Andrew Cleeland is the CEO of Fogarty Innovation. He is also the chairman of Frances Medical. A seasoned executive with more than 30 years of experience in the medical device industry, Andrew has held key leadership positions in organizations ranging from early-stage start-ups to large multinationals. 

After completing his undergraduate degree in biophysics at the Swinburne Institute of Technology, Andrew began his career working for the Australian Therapeutic Goods Administration. He went on to positions at two large medtech companies, Telectronics Pacing Systems and Baxter Healthcare, before moving into the Silicon Valley start-up space as vice president of clinical and regulatory affairs at Radiant Medical. His next role was as the CEO of Ardian, which pioneered the use of renal denervation to treat hypertension. Ardian was acquired by Medtronic with Andrew leading the new division as a Vice President/General Manager. He then went on to a role as CEO at Twelve, a startup in the transcatheter mitral valve space. It was also acquired by Medtronic with Andrew leading Medtronic’s transcatheter mitral valve program until he joined Fogarty Innovation. 

Andrew currently serves on the board of five venture-funded companies — Saluda Medical, Zenflow, Inc. (chairman), MMI Inc. (chairman), atHeart Medical, and Francis Medical. He also holds advisory positions at two top-tier venture capital firms: Longitude Capital and Arboretum Ventures. At a global industry level, he has been invited to serve on multiple initiatives including the UCSF-Stanford Pediatric Device Consortium; the Medical Device Innovation Consortium; and the Singapore government’s Biomedical Research Council (BMRC). 

Andrew has received numerous awards and honors and is a frequently invited lecturer at major industry conferences and leading academic institutions.